Proteus mirabilis

Magalhaes VD, et al. 1998. Biochim Biophys Acta 1443(1-2): 262-266. A new tetracycline resistance determinant cloned from Proteus mirabilis. (PMID 9838156)

Cambau E, et al. 2006. Clin Microbiol Infect 12(10): 1013-1020. Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002-2005. (PMID 16961639)

Boyd DA, et al. 2007. Antimicrob Agents Chemother 52(1): 340-344. Salmonella genomic island 1 (SGI1), variant SGI1-I, and new variant SGI1-O in proteus mirabilis clinical and food isolates from China. (PMID 18025121)

McGettigan SE, et al. 2009. J Clin Microbiol 47(9): 2970-2974. Prevalence of CTX-M beta-lactamases in Philadelphia, Pennsylvania. (PMID 19587301)

Decre D, et al. 2002. J Antimicrob Chemother 50(5): 681-688. Characterization of CMY-type beta-lactamases in clinical strains of Proteus mirabilis and Klebsiella pneumoniae isolated in four hospitals in the Paris area. (PMID 12407124)

Verdet C, et al. 1998. FEMS Microbiol Lett 169(2): 235-240. Characterisation of CMY-4, an AmpC-type plasmid-mediated beta-lactamase in a Tunisian clinical isolate of Proteus mirabilis. (PMID 9868767)

Jones CH, et al. 2009. Antimicrob Agents Chemother 53(3): 977-986. Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155. (PMID 19075050)

Aragon LM, et al. 2008. J Antimicrob Chemother 61(5): 1029-1032. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases. (PMID 18292096)

Naas T, et al. 2002. Antimicrob Agents Chemother 47(1): 19-26. Integration of a transposon Tn1-encoded inhibitor-resistant beta-lactamase gene, bla(TEM-67) from Proteus mirabilis, into the Escherichia coli chromosome. (PMID 12499163)

Ho PL, et al. 2005. J Antimicrob Chemother 55(6): 840-845. Occurrence and molecular analysis of extended-spectrum {beta}-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002. (PMID 15857942)

Literacka E, et al. 2004. Antimicrob Agents Chemother 48(11): 4136-4143. Four variants of the Citrobacter freundii AmpC-Type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a Proteus mirabilis clone widespread in Poland. (PMID 15504832)

D'Andrea MM, et al. 2011. Antimicrob Agents Chemother 55(6): 2735-2742. Evolution and spread of a multidrug-resistant Proteus mirabilis clone with chromosomal AmpC-type cephalosporinases in Europe. (PMID 21402851)

Perilli M, et al. 2002. Antimicrob Agents Chemother 46(3): 925-928. Characterization of a new extended-spectrum beta-lactamase (TEM-87) isolated in Proteus mirabilis during an Italian survey. (PMID 11850290)

De Champs C, et al. 2004. J Antimicrob Chemother 54(3): 634-639. Frequency and diversity of Class A extended-spectrum beta-lactamases in hospitals of the Auvergne, France: a 2 year prospective study. (PMID 15282240)

Navon-Venezia S, et al. 2008. J Antimicrob Chemother 62(2): 289-295. Dissemination of the CTX-M-25 family beta-lactamases among Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and identification of the novel enzyme CTX-M-41 in Proteus mirabilis in Israel. (PMID 18487232)

Saladin M, et al. 2002. FEMS Microbiol Lett 209(2): 161-168. Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. (PMID 12007800)

D'Andrea MM, et al. 2006. Antimicrob Agents Chemother 50(2): 618-624. CMY-16, a novel acquired AmpC-type beta-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy. (PMID 16436718)

Empel J, et al. 2008. Antimicrob Agents Chemother 52(7): 2449-2454. Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals. (PMID 18458126)

Neuwirth C, et al. 2001. Antimicrob Agents Chemother 45(12): 3591-3594. TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3. (PMID 11709345)

Schneider I, et al. 2013. Antimicrob Agents Chemother 58(1): 620-621. Detection of CMY-99, a novel acquired AmpC-Type beta-lactamase, and VIM-1 in Proteus mirabilis isolates in Bulgaria. (PMID 24165184)

Gionechetti F, et al. 2008. Microb Drug Resist 14(2): 93-99. Characterization of antimicrobial resistance and class 1 integrons in Enterobacteriaceae isolated from Mediterranean herring gulls (Larus cachinnans). (PMID 18476779)

Charles IG, et al. 1985. J Bacteriol 164(1): 123-129. Nucleotide sequence analysis of the cat gene of Proteus mirabilis: comparison with the type I (Tn9) cat gene. (PMID 3900035)

Wang M, et al. 2009. Antimicrob Agents Chemother 53(5): 1892-1897. New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. (PMID 19258263)

Wu JJ, et al. 2008. Diagn Microbiol Infect Dis 60(2): 169-175. Prevalence of extended-spectrum beta-lactamases in Proteus mirabilis in a Taiwanese university hospital, 1999 to 2005: identification of a novel CTX-M enzyme (CTX-M-66). (PMID 17913434)

Zong Z, et al. 2009. Antimicrob Agents Chemother 53(4): 1693-1697. A blaVEB-1 variant, blaVEB-6, associated with repeated elements in a complex genetic structure. (PMID 19139283)

Zong Z, et al. 2008. Antimicrob Agents Chemother 52(2): 794-795. RmtC 16S rRNA methyltransferase in Australia. (PMID 18025117)